July 1, 2022

Medical Trend

Medical News and Medical Resources

CAR-T milestone patent and global overview

CAR-T milestone patent and global overview

 

CAR-T milestone patent and global overview.  including milestone patents, top inventors, assignee, transferee collaboration andGeographical distribution,etc.

 

CAR-T Milestone Patents:

WO2005044996
St. Jude Children’s Research Hospital
Chimeric receptors with 4-1BB stimulatory signaling domain

US9834590
St. Jude Children’s Research Hospital
Chimeric receptors with 4-1BB stimulatory signaling domain

WO2007059298
City of Hope
Chimeric immunoreceptor useful in treating human cancers

WO2008043777
University of Nantes
Use of monoclonal antibodies specific to the O-acetylated form of GD2 ganglioside for the treatment of certain cancers

WO2008121420
Memorial Sloan Kettering Cancer Center
Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes

WO2009091826
University of Texas System
Compositions and methods related to a human CD19-specific chimeric antigen receptor (h-CAR)

WO2011056894
City of Hope
Truncated epidermal growth factor receptor (EGFRt) for transduced T cell selection

WO2012079000
University of Pennsylvania
Use of chimeric antigen receptor modified T-cells to treat cancer

WO2012129514
Fred Hutchinson Cancer Research Center
Method and compositions for cellular immunotherapy

WO2013123061
Seattle Children’s Hospital
Bispecific chimeric antigen receptors and encoding polynucleotides thereof

WO2014153270
Novartis and University of Pennsylvania
Treatment of cancer using humanized anti-CD19 chimeric antigen receptor

WO2015142675
Novartis and University of Pennsylvania
Treatment of cancer using chimeric antigen receptor

WO2017025038
Legend Biotech
Chimeric antigen receptors based on single-domain antibodies and methods of use thereof

WO2017172981
University of Southern California
Chimeric antigen receptors targeting cancer

WO2019076149
Chongqing Precision Biotech
Universal CAR-T cell preparation, method therefor and application thereof

CN109055380
Fapon Biopharma
A preparation method for universal CAR-T cells

CAR-T milestone patent and global overview

 

 



Top 20 inventors

CAR-T milestone patent and global overview

 

Top20 assignees

CAR-T milestone patent and global overview

 

 

Transferee collaboration

CAR-T milestone patent and global overview

 

The University of Pennsylvania and Novartis have the closest cooperative relationship.


Consolidate assignees headquartered in the same area and convert the institutional network to a regional network. The United States has a dominant position in collaboration; the United States and Switzerland are a unique collaborative pair with the highest frequency of collaboration.

In contrast, although China is the second largest node after the United States, it has relatively little cooperation with neighboring countries Japan and South Korea.

 

Geographical distribution

The United States first issued CAR-T patents in 2005, and France and other major countries issued CAR-T patents in 2008 and 2012 respectively. Since 2017, the number of patents filed by Chinese assignees ranks second, although they are still less than one-tenth of the total number of US patents.

The United States Patent Office (USPTO) and China National Intellectual Property Office (CNIPA) have been filing a close number of patent applications; in 2016, China (n=119) surpassed the United States (n=107) for the first time. Patent applications have maintained a relatively stable growth trend in the European Patent Office and the Japanese Patent Office. However, since 2018, Canada has received a sharp decline in patents.

CAR-T milestone patent and global overview

 

Target distribution

Among the top 20 targets, CD19 is the most common, followed by BCMA and CD20. The American and Chinese assignees cover all targets and are in a leading position in all top targets.


Reference network

WO2012079000 (using chimeric antigen receptor modified T cells to treat cancer) and WO2014153270 (Novartis CD19) are cited the most.

The pink clusters mainly focus on allogeneic cells and related methods, such as WO2013176915 (methods for engineering allogeneic and immunosuppression-resistant T cells for immunotherapy), WO2014191128 (methods for engineering T cells for immunotherapy by using an RNA-guided Cas nuclease system) ) And WO2014039523 (multi-chain chimeric antigen receptor and uses thereof). These three patents have the same assignee, the French biopharmaceutical company Celectis.

 

 

 

 

 

(source:internet, reference only)


Disclaimer of medicaltrend.org